Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein
- PMID: 21292876
- PMCID: PMC3032488
- DOI: 10.4269/ajtmh.2011.09-0507
Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein
Abstract
Plasmodium vivax circumsporozoite (CS) protein is a leading malaria vaccine candidate. We describe the characterization of specific immune responses induced in 21 malaria-naive volunteers vaccinated with long synthetic peptides derived from the CS protein formulated in Montanide ISA 720. Both antibody- and cell-mediated immune responses were analyzed. Antibodies were predominantly of IgG1 and IgG3 isotypes, recognized parasite proteins on the immunofluorescent antibody test, and partially blocked sporozoite invasion of hepatoma cell lines in vitro. Peripheral blood mononuclear cells from most volunteers (94%) showed IFN-γ production in vitro upon stimulation with both long signal peptide and short peptides containing CD8+ T-cell epitopes. The relatively limited sample size did not allow conclusions about HLA associations with the immune responses observed. In summary, the inherent safety and tolerability together with strong antibody responses, invasion blocking activity, and the IFN-γ production induced by these vaccine candidates warrants further testing in a phase II clinical trial.
Figures
Similar articles
-
Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):12-20. doi: 10.4269/ajtmh.2011.09-0516. Am J Trop Med Hyg. 2011. PMID: 21292873 Free PMC article. Clinical Trial.
-
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423. eCollection 2016 Feb. PLoS Negl Trop Dis. 2016. PMID: 26919472 Free PMC article. Clinical Trial.
-
Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine.Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):3-9. doi: 10.4269/ajtmh.2005.73.3. Am J Trop Med Hyg. 2005. PMID: 16291760 Clinical Trial.
-
Live attenuated pre-erythrocytic malaria vaccines.Hum Vaccin Immunother. 2014;10(10):2903-9. doi: 10.4161/21645515.2014.972764. Hum Vaccin Immunother. 2014. PMID: 25483648 Free PMC article. Review.
-
Vaccination for vivax malaria: targeting the invaders.Trends Parasitol. 2004 Mar;20(3):99-102. doi: 10.1016/j.pt.2003.12.003. Trends Parasitol. 2004. PMID: 16676415 Review.
Cited by
-
Alternative Invasion Mechanisms and Host Immune Response to Plasmodium vivax Malaria: Trends and Future Directions.Microorganisms. 2020 Dec 23;9(1):15. doi: 10.3390/microorganisms9010015. Microorganisms. 2020. PMID: 33374596 Free PMC article. Review.
-
Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.PLoS One. 2013;8(2):e56061. doi: 10.1371/journal.pone.0056061. Epub 2013 Feb 14. PLoS One. 2013. PMID: 23457498 Free PMC article.
-
Increased interleukin-10 and interferon-γ levels in Plasmodium vivax malaria suggest a reciprocal regulation which is not altered by IL-10 gene promoter polymorphism.Malar J. 2011 Sep 14;10:264. doi: 10.1186/1475-2875-10-264. Malar J. 2011. PMID: 21917128 Free PMC article.
-
Clinical and epidemiological aspects of complicated malaria in Colombia, 2007-2013.Malar J. 2016 May 10;15(1):269. doi: 10.1186/s12936-016-1323-5. Malar J. 2016. PMID: 27165306 Free PMC article.
-
Recombinant Plasmodium vivax circumsporozoite surface protein allelic variants: antibody recognition by individuals from three communities in the Brazilian Amazon.Sci Rep. 2020 Aug 20;10(1):14020. doi: 10.1038/s41598-020-70893-3. Sci Rep. 2020. PMID: 32820195 Free PMC article.
References
-
- Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97–106. - PubMed
-
- Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig RS, Clyde D, Edelman R. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg. 1991;45:539–547. - PubMed
-
- Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185:1155–1164. - PubMed
-
- Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol. 1984;132:909–913. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials